Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Discovery of a Novel DNMT1 Inhibitor with Improved Efficacy in Treating β-Thalassemia [WGBS]

ABSTRACT: The β-thalassemia is a recessively inherited disease affecting millions around the world. Pharmacological induction of fetal hemoglobin (HbF) is an effective therapeutic strategy for the management of β-thalassemia. DNA methyltransferase inhibitors are effective HbF inducers, however was not currently approved for β-thalassemia treatments. Here we report that the newly developed non-nucleoside DNMT1 inhibitor DMT207 strongly reactivates the expression of HbF in HUDEP-2 cells and adult primary erythroblasts with minimal toxicity. Moreover, in a mouse model of β-thalassemia, the administration of DMT207 effectively induces the expression of mouse fetal- and embryonic-type hemoglobin, promotes the maturation of erythroid cells, and alleviates the splenomegaly of mice. Further multi-omics studies expose γ-globin as one of the most sensitive genes in response to DMT207 treatment. Mechanistically, DMT207 inhibits DNMT1 enzymatic activity through trapping DNMT1 into an open conformation and meanwhile enhances interactions between the conformationally-kinked DNMT1 and UHRF1, partially contributing to specific degradation of DNMT1. Thus, we conclude that DMT207 is a promising novel DNMT1 inhibitor that could benefit patients with β-thalassemia.

ORGANISM(S): Homo sapiens

PROVIDER: GSE298943 | GEO | 2026/03/04

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Discovery of a Novel DNMT1 Inhibitor with Improved Efficacy in Treating β-Thalassemia [RNA-seq]

Project description:The β-thalassemia is a recessively inherited disease affecting millions around the world. Pharmacological induction of fetal hemoglobin (HbF) is an effective therapeutic strategy for the management of β-thalassemia. DNA methyltransferase inhibitors are effective HbF inducers, however was not currently approved for β-thalassemia treatments. Here we report that the newly developed non-nucleoside DNMT1 inhibitor DMT207 strongly reactivates the expression of HbF in HUDEP-2 cells and adult primary erythroblasts with minimal toxicity. Moreover, in a mouse model of β-thalassemia, the administration of DMT207 effectively induces the expression of mouse fetal- and embryonic-type hemoglobin, promotes the maturation of erythroid cells, and alleviates the splenomegaly of mice. Further multi-omics studies expose γ-globin as one of the most sensitive genes in response to DMT207 treatment. Mechanistically, DMT207 inhibits DNMT1 enzymatic activity through trapping DNMT1 into an open conformation and meanwhile enhances interactions between the conformationally-kinked DNMT1 and UHRF1, partially contributing to specific degradation of DNMT1. Thus, we conclude that DMT207 is a promising novel DNMT1 inhibitor that could benefit patients with β-thalassemia.

2026-03-04 | GSE298942 | GEO

Discovery of a Novel DNMT1 Inhibitor with Improved Efficacy in Treating β-Thalassemia [ATAC-seq]

2026-03-04 | GSE298941 | GEO

Development of pathophysiologically relevant models of sickle cell disease and β-thalassemia for therapeutic studies

Project description:β-hemoglobin disorders, such as sickle cell disease (SCD) and β-thalassemia (BT), are the most common inherited monogenic blood disorders globally. Despite decades of research, there are only four FDA-approved medications available for the management of SCD with hydroxyurea (HU) being the most widely used drug that partially benefits patients by inducing fetal hemoglobin (HbF) production. On the other hand, there are no approved oral drugs currently available for β-thalassemia patients. To our knowledge, there are currently no well-characterized erythroid progenitor cell lines available that can accurately replicate the pathophysiology of SCD and BT while also having the same genetic background apart from the disease mutation enabling consistency and reproducibility. Our novel, physiologically relevant cellular systems provide a plethora of avenues for researchers to investigate various applications related to parasite invasion, drug validation, and genome-editing in the context of SCD and BT.

2024-02-07 | PXD044642 | Pride

Global transcriptions upon MAZ knockdown HUDEP-2 cells

Project description:Hemoglobinopathies, such as sickle cell disease and β-thalassemia, are common genetic disorders remaining significant global health challenges due to their associated morbidity and mortality. Increasing fetal hemoglobin (HbF) levels has emerged as a promising therapeutic strategy for these disorders. In this study, we report MAZ as a repressor of γ-globin expression in human erythroid cells. Depletion of MAZ in HUDEP-2 and patient-derived β-thalassemia cells leads to significant inductions both of γ-globin mRNA and protein levels, resulting in increased HbF percentages and HbF+ erythroid cells. We demonstrate that MAZ occupies at the MYB promoter. MAZ depletion reduced MYB and BCL11A levels. Restoration of MYB re-silenced the γ-globin levels in MAZ depleted cells. Our findings uncover the MAZ-MYB axis in γ-globin regulation, highlighting MAZ as a potential target to enhance HbF levels in patients with hemoglobin disorders.

2025-11-01 | GSE281501 | GEO

The circRNA expression profiles of reticulocytes for β-thalssemia carriers with high fetal hemoglobin

Project description:To explore the involvement of circRNAs in β-thalassemia and their actions on fetal hemoglobin (HbF), we surveyed circRNA expression profiles using circulating reticulocytes isolated from individuals with β-thalassaemia carriers with high HbF.

2022-05-27 | GSE196682 | GEO

Epigenetic inactivation of ERF reactivates γ-globin expression in β-thalassemia [ChIP-seq]

Project description:The fetal-to-adult hemoglobin switch is regulated in a developmental stage-specific manner and reactivation of fetal hemoglobin (HbF) has therapeutic potential for β-hemoglobinopathies. Although BCL11A and ZBTB7A interact with their coregulators, reportedly mediating most γ-globin transcriptional silencing in erythroid in trans, and in cis, the molecular mechanism underlying the epigenetic dysregulation of the switch remains largely unclear. Here we showed that epigenetic inactivation of an ETS2 repressor factor (ERF) reactivates γ-globin expression during stress erythropoiesis, and ERF depletion elevates γ-globin in erythroid cells and in erythroid progenies from the edited HSPCs engrafted into immunodeficient mice. ERF represses γ-globin by directly binding to two motifs regulating HBG expression, independently of the major HbF repressors BCL11A and ZBTB7A. We further uncovered that an lncRNA, RP11-196G18.23 mediates ERF promoter hypermethylation resulting in reactivation of g-globin. Herein, the epigenetic alterations were identified as novel modulators ameliorating the severity of b-thalassemia, thus providing novel therapeutic targets for β-hemoglobinopathies.

2020-12-27 | GSE160602 | GEO

Epigenetic inactivation of ERF reactivates γ-globin expression in β-thalassemia [RNA-seq]

2020-12-27 | GSE160601 | GEO

Single-cell transcriptomics reveals heterocellular g-globin gene expression in Agdb-thalassemia

Project description:To determine the heterogeneity of g-globin expression in the context of deletions that induce fetal hemoglobin, single-cell RNA-seq was performed on primary reticulocytes and undifferentiated HUDEP-2 cells. Single-cell RNA-sequencing (10x Genomics) showed participants and cell lines with the Agdb-thalassemia deletion had overall lower g-globin expression and maintained a lower %HBG expression (HBG/(HBG+HBB)) compared to participants and cell lines with deletional HPFH.

2026-02-25 | GSE280004 | GEO

Identification of a rare Asian Indian Deletion [Gγ(Aγδβ)0] Delta-Beta Thalassemia using High Resolution Mass Spectrometry

Project description:Delta-Beta thalassemia is an unusual variant of thalassemia caused by large deletions in the β globin gene cluster involving δ- and β-globin genes. The mutations are characterized by high fetal hemoglobin with significant phenotypic diversity. Routinely used diagnostic tests targeting point mutations and small insertions, deletions of the β-globin gene are not suitable for detection of large deletion mutations. This is overcome by either direct globin chain synthesis analysis or beta-cluster gene analysis using different methods. In the current study, we use direct globin chain analysis to diagnose a family with δβ-thalassemia using high resolution mass spectrometry.

2024-08-09 | PXD044775 | Pride

Transcription profiling of mouse erythroleukemia (MEL) cells expressing tagged versions of BCL11A

Project description:Differences in the amount of fetal hemoglobin (HbF) that persists into adulthood affect the severity of sickle cell disease and the beta-thalassemia syndromes. Genetic association studies have identified sequence variants in the gene BCL11A that influence HbF levels. Here we examine BCL11A as a potential regulator of HbF expression. The high HbF BCL11A genotype is associated with reduced BCL11A expression. Moreover, abundant expression of full-length forms of BCL11A is developmentally restricted to adult erythroid cells. Down-regulation of BCL11A expression in primary adult erythroid cells leads to robust HbF expression. Consistent with a direct role of BCL11A in globin gene regulation, we find that BCL11A occupies several discrete sites in the beta-globin gene cluster. BCL11A emerges as a therapeutic target for reactivation of HbF in beta-hemoglobin disorders. Expression clone label: FBB (4 different subclones, with 2 arrays each), Control label: MelBirA Experiment Overall Design: Microarray expression analysis from parental control mouse erythroleukemia (MEL) cells containing the BirA enzyme (MelBirA cells) and cells containing tagged versions (FLAG-Biotag) of BCL11A. Two control datasets and eight datasets from four subclones containing tagged BCL11A are included.

2009-01-13 | E-GEOD-13283 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data